Opexa Therapeutics, Inc. announced that Neil K. Warma, the company’s President and Chief Executive Officer, recently served as a panelist at the New York CEO Conference, which was held from November 12 – 13, 2014 in New York.
Woodlands-based Opexa is a biopharmaceutical company focused on developing personalized immunotherapies to treat major illnesses such as multiple sclerosis, neuromyelitis optic, and other autoimmune diseases. Opexa uses T-cell technology from which Tcelna® (formerly know as tovaxin) is their leading therapy candidate; it is derived from T-cells isolated from the patient’s blood, expanded artificially ex vivo, and reintroduced into the respective previous owner again through subcutaneous injections. This process triggers a strong immune response against specific, dangerous subsets. Opexa intends to lead the field of Precision Immunotherapy and to fulfill the unmet needs of patients, employees, and shareholders. Tcelna® was granted the Fast Track status by the Food and Drug Administration (FDA) in secondary progressive multiple sclerosis.
This event is one in a series that the company has recently participated in. After being invited to host a presentation at the Cleveland Clinic’s 12th Annual Medical Innovation Summit, Mr. Warma joined other experts in this area of knowledge to discuss the advances that are being made in the industry and its implications for drug development. “How is Personalized Medicine Guiding Drug Development in 2014?,” a topic germane to Opexa’s own technologies, was the first discussion held on the second day, after opening remarks.
The New York CEO Conference is a forum for industry CEOs (Chief Executive Officers) and decision makers in the life sciences field. Participation in the conference is invitation-only, and focuses on luminaries in medicine and research, as well as leading biotechnology and pharmaceutical company executives that discuss relevant issues related to the industry. The topics that were included this year included an outlook on the 2015 healthcare industry, the relevance of accelerating translation of research results and outcomes, financial strategies, the role of innovation in the drug discovery field, personalized medicine, and innovative business structures.